3 ms·
That is not what this paper reports, and the title should be de-editorialised. Compared to 1,918 conventionally treated patients we observed a survival benefit
by hprotagonist 7y ago
That is not what this paper reports, and the title should be de-editorialised.
Compared to 1,918 conventionally treated patients we observed a survival benefit for ivermectin (mortality rate 18.6% vs 7.7%; HR 0.18, 95% CI (0.07-0.48), log rank (Mantel-Cox) p<0.001). The hospital length of stay was 15.7 +/- 8.1 days vs 10.9 +/- 6.1 days, p<0.001 and intensive care unit length of stay 8.2 +/- 6.2 days vs 6.0 +/- 3.9 days, p<0.001 respectively.
In COVID-19 illness, critically ill patients with lung injury requiring mechanical ventilation may benefit from administration of Ivermectin. We noted a lower mortality and reduced healthcare resource use in those treated with ivermectin. These observations should not be considered definitive and allow for translation of a hypothesis from bench to bedside which will require confirmation in a controlled clinical trial setting.